Eli Lilly reported that its oral GLP‑1 candidate orforglipron met primary and key secondary endpoints in a Phase 3 maintenance trial, helping participants maintain weight lost on injectable GLP‑1 therapies. The company has submitted orforglipron to the FDA and received a national‑priority review voucher, shortening the anticipated review timeline. The trial re‑randomized participants who previously lost weight on Wegovy or Zepbound and found superior weight‑maintenance versus placebo over 52 weeks. Lilly frames the pill as a maintenance option for patients transitioning off or supplementing injectables. Regulatory momentum and the voucher could accelerate market entry and shape competitive positioning versus Novo Nordisk’s oral programs; clinicians will watch durability, safety and real‑world adherence data.